Add BrightSurf on Google Email

Nano-radiomics unveils treatment effect on tumor microenvironment

Researchers developed a noninvasive method to assess the effect of cellular immunotherapies on the tumor microenvironment, which inhibits the immune response and evades cancer treatments. Nano-radiomics combines imaging technology with radiomics to analyze changes in the TME that conventional methods cannot detect.

SourceBaylor College of Medicine·JournalJournal of Mathematical Sciences Advances and Applications·DateJul 10, 2020

Call for caution for using a CAR-T immunotherapy against acute myeloid leukemia

The use of CAR-T immunotherapy against acute myeloid leukemia is being reevaluated due to concerns over its impact on healthy hematopoietic stem and progenitor cells. Studies have shown that anti-CD123 CAR T-cells can inhibit normal hematopoiesis, leading to irreversible impairment in blood cell formation.

SourceJosep Carreras Leukaemia Research Institute·JournalJournal for ImmunoTherapy of Cancer·DateJun 17, 2020

Mapping immune cells in brain tumors

A study by researchers at the University of Zurich mapped immune cells in different types of brain tumors, revealing tumor-specific instructions for tissue-invasive leukocytes. The findings provide a basis for developing tailored immunotherapies for various types of brain tumors.

SourceUniversity of Zurich·JournalCell·DateMay 28, 2020

Predicting immunotherapy success

Weizmann Institute researchers found that overexpression of specific immunoproteasome subunits in melanoma is tied to anti-cancer immune activity. The study's findings suggest that these biomarkers may improve patient matching to current immunotherapy treatments, leading to better outcomes.

SourceWeizmann Institute of Science·JournalNature Communications·DateFeb 18, 2020

Math models add up to improved cancer immunotherapy

Researchers at Massachusetts General Hospital developed mathematical models to predict how tumors may respond to immunotherapy and how adding other anti-cancer drugs could lead to improved treatment. The models suggest that normalization of the tumor microenvironment, including blood supply, could improve treatment efficacy.

SourceMassachusetts General Hospital·JournalProceedings of the National Academy of Sciences·DateFeb 3, 2020

Electronic nose can sniff out which lung cancer patients will respond to immunotherapy

A new electronic nose can identify lung cancer patients who will respond to immunotherapy with 85% accuracy, outperforming the current gold standard of immunohistochemistry. The non-invasive test detects chemicals in patient breath and provides instant feedback, potentially avoiding ineffective treatment and side effects.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateSep 17, 2019